Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 6/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978011 | 0.89 | PTGDR2 (0.46) | PTGDR2MAP4K4CNR2CNR1MAPT | |
| SCHEMBL412169 | 0.85 | KMO (0.52) | KMOCNR2MRGPRX4 | |
| SCHEMBL411991 | 0.85 | KMO (0.42) | KMOCNR2MRGPRX4 | |
| SCHEMBL411996 | 0.84 | KMO (0.41) | KMOCNR2L3MBTL1ASPH | |
| SCHEMBL411891 | 0.83 | MAP4K4 (0.49) | PTGDR2KMOMAP4K4CNR2MAPT | |
| SCHEMBL27924396 | 0.83 | KMO (0.40) | PTGDR2KMOCNR2MRGPRX4KDM2B | |
| SCHEMBL27906390 | 0.83 | KMO (0.43) | KMOCNR2MRGPRX4KDM2BKDM4C | |
| SCHEMBL410983 | 0.81 | CNR1 (0.48) | PTGDR2KMOMAP4K4CNR1MRGPRX4 | |
| SCHEMBL442683 | 0.81 | PTGDR2 (0.44) | PTGDR2MAP4K4CNR2CNR1L3MBTL1 | |
| SCHEMBL440891 | 0.80 | MAP4K4 (0.44) | PTGDR2KMOMAP4K4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | claimed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | claimed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | claimed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | claimed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3074400-B1 | OCTAHYDRO-CYCLOBUTA [1,2-C;3,4-C']DIPYRROLE DERIVATIVES AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| CN-103118680-B | Heteroaryl carboxamides | HOFFMAN-LA ROCHE LTD. (CH) | 2015-12-16 | — | — | CN | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | PTGDR2 665/4885KMO 747/4885MAP4K4 3265/4885 |
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | PTGDR2 854/4885KMO 1057/4885MAP4K4 3549/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | PTGDR2 2386/4885KMO 2423/4885MAP4K4 4374/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | PTGDR2 738/4885KMO 802/4885MAP4K4 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.